Tuba Esfandyari, M.D, M.Sc.

Professional Background

Dr. Esfandyari has completed her internal medicine internship at Cleveland Clinic Health System, OH, 2000-2001, internal medicine residency training at University of Massachusetts, 2021-2003. and gastroenterology fellowship at Mayo Clinic, MN, 2003-2006.
She completed a self-directed training in advanced 3rd space therapeutic endoscopy, Endoscopic Submucosal Dissection (ESD) for treatment of early GI malignancies, per-Oral Endoscopic Myotomies (POEMs) for GI motility disorders such as gastroparesis, achalasia,.., Endoscopic Surgery for reflux disease and Bariatric Endoscopy, at ASGE animal laboratories and Harvard Medical School in 2018-2019.
She holds 2 Master's Degrees (M.Sc.); Gastrointestinal Neuroscience from University of Calgary, CANADA, 1997-1999 and Master's Degree in Clinical Research from Mayo Clinic, MN, 2004-2008.
She is an Associate Professor of Medicine in division of gastroenterology, hepatology and motility at The University of Kansas, Kansas City. She is Director of GI Motility Group at The University of Kansas Health System.
She is actively participating in clinical research. she had completed more than 50 clinical trials over past 10 years and is currently the principal investigator (PI) to 15 active clinical trials.
Dr Esfandyari is passionate in educating medical students, residents and fellows. She has mentored many medical students, residents and fellows throughout their trainings and career paths.

• MD, M.D., Tabriz University of Medical sciences (Combined Degree, 7 years Medical school, 2 yrs pre clinical, 3 yrs clinical and 2 yrs postgraduate training), Tabriz, Tabriz
• Internship, Internal Medicine, Cleveland Clinic Health System, Cleveland , OH
• Residency, Internal Medicine, University of Massachusetts,, Worcester, MA
• Clinical Fellowship, Gastroenterology, Mayo Clinic, Rochester, Rochester, MN
• Other, Clinical Research and Biostatistics, Mayo Clinic, Rochester, Rochester, MN
• Other, Gastrointestinal Neurosciences, University of Calgary, Canada, Calgary, Alberta

• Kansas Medical License , Kansas State Board of Healing Arts

• American College of Gastroenterology, Member, 2003 - Present
• American Gastroenterological Association, Member, 2003 - Present
• American Society for Gastrointestinal Endoscopy, Member, 2003 - Present

---

• Ichkhanian Yervant, Salame Marita, Wo John, Nowak Thomas, Stainko Sarah, Saito Akira, Siwiec Robert, Hwang Joo Ha, Li Andrew, Yang Juliana, Broucek Joseph, Esfandyari Tuba, Joseph Stephanie, Ujiki Michael, Williams Ashley, Moremen Jacob, Gouda Zane, Schlachterman Alexander, Hugova Kristina, Martinek Jan, Geng Calvin, Podboy Alexander, Wang Andrew, Lajin Michael, Gregor Lennon, Albunni Hashem, Dewitt John, Al-Haddad Mohammad. 2024. A COMPREHENSIVE ANALYSIS ON THE DIAGNOSIS AND THE MANAGEMENT OF CLINICAL FAILURE POST GASTRIC PERORAL ENDOSCOPIC MYOTOMY: AN INTERNATIONAL COHORT STUDY. Gastrointestinal Endoscopy, 99 (6), AB1130-AB1131. https://doi.org/10.1016/j.gie.2024.04.2859
• Abell Thomas L, Kuo Braden, Esfandyari Tuba, Pfeifer Nathan D, Grimaldi Maria, Renzulli Cecilia, Tacchi Raffaella, Zhou Kefei, Barnes Chris N, Nguyen Deanna D, Nguyen Linda, Talley Nicholas J, McCallum Richard. 2023. A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. Neurogastroenterology & Motility, 35 (4). https://doi.org/10.1111/nmo.14523
• Ejskjaer N, Wo JM, Esfandyari T, Jamal Mazin, Dimcevski G, Tarnow L, Malik RA, Hellström PM, Mondou E, Quinn J, Rousseau F, McCallum RW. 2013. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.. Neurogastroenterology and Motility, 25 (2), 140-150
• Terai Kaoru, Bi Danse, Liu Zhengian, Kimura Kyle, Sanaat Zohreh, Dolatkhah Roya, Soleimani Mina, Jones Christopher, Bright Allison, Esfandyari Tuba, Farassati Faris. 2018. A Novel Oncolytic Herpes Capable of Cell-Specific Transcriptional Targeting of CD133± Cancer Cells Induces Significant Tumor Regression. Stem Cells, 36 (8), 1154-1169. https://doi.org/10.1002/stem.2835